SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Want to cut your energy bills? Here’s how five experts are doing it 
NEWARK, Calif., March 06, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that senior management will present at the following healthcare conferences during the month of March.
29th Annual ROTH Conference
Date: Monday, March 13, 2017
Time: 3:00 p.m. PDT
Location: Dana Point, CaliforniaOppenheimer 27th Annual Healthcare Conference
Date: Tuesday, March 21, 2017
Time: 8:30 a.m. EDT
Location: New York, New York
These presentations will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
